Receptor
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
Receptor | 18 November 2011
-
IMBcom and Prolor Biotech Sign Non-Exclusive Technology License
The University of Queensland’s (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB) – has announced that Prolor Biotech has taken out a non-exclusive license to UQ’s human growth hormone receptor cell l…
Receptor | 01 September 2009
-
GVK Biosciences Announces Agreement with University of Tokyo on GPCR Database
GVK Biosciences has entered into an agreement with Dr Kimito Funatsu, University of Tokyo on G-protein Coupled Receptor (GPCR) databases. The agreement covers the GPCR class of targets curated at the company. Dr Funatsu will utilize the manually …
Receptor | 02 July 2009
-
Food Peptides Activate Bitter Taste Receptors
Researchers from the Monell Center and Tokyo University of Agriculture have used a novel molecular method to identify chemical compounds from common foods that activate human bitter taste receptors. The findings, published in the journal Biochemi…
Receptor | 04 February 2008
